<--- Back to Details
First PageDocument Content
Lymphoma / Histone deacetylase inhibitor / Cutaneous T-cell lymphoma / Romidepsin / Vorinostat / Histone deacetylase / Merck & Co. / Mesothelioma / Targeted therapy / Medicine / Pharmacology / Orphan drugs
Date: 2010-10-19 13:01:20
Lymphoma
Histone deacetylase inhibitor
Cutaneous T-cell lymphoma
Romidepsin
Vorinostat
Histone deacetylase
Merck & Co.
Mesothelioma
Targeted therapy
Medicine
Pharmacology
Orphan drugs

Mesothelioma Articles - Merck & Co: Zolinza becomes first app...

Document is deleted from original location.
Use the Download Button below to download from the Web Archive.

Download Document from Web Archive

File Size: 39,24 KB